10/04/2019 12:45:00

Investor Expectations to Drive Momentum within Analog Devices, Atara Biotherapeutics, Cigna, Solaris Oilfield Infrastructure, Erie Indemnity, and Dova Pharmaceuticals — Discovering Underlying Factors of Influence

NEW YORK, April 10, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Analog Devices, Inc. (NASDAQ:ADI), Atara Biotherapeutics, Inc. (NASDAQ:ATRA), Cigna Corporation (NYSE:CI), Solaris Oilfield Infrastructure, Inc. (NYSE:SOI), Erie Indemnity Company (NASDAQ:ERIE), and Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

ADI DOWNLOAD: https://MarketSourceResearch.com/register/?so=ADI

ATRA DOWNLOAD: https://MarketSourceResearch.com/register/?so=ATRA

CI DOWNLOAD: https://MarketSourceResearch.com/register/?so=CI

SOI DOWNLOAD: https://MarketSourceResearch.com/register/?so=SOI

ERIE DOWNLOAD: https://MarketSourceResearch.com/register/?so=ERIE

DOVA DOWNLOAD: https://MarketSourceResearch.com/register/?so=DOVA

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Market Source Research, available for free download at the links above, examine Analog Devices, Inc. (NASDAQ:ADI), Atara Biotherapeutics, Inc. (NASDAQ:ATRA), Cigna Corporation (NYSE:CI), Solaris Oilfield Infrastructure, Inc. (NYSE:SOI), Erie Indemnity Company (NASDAQ:ERIE), and Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice:

the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

ANALOG DEVICES, INC. (ADI) REPORT OVERVIEW

Analog Devices' Recent Financial Performance

For the three months ended January 31st, 2019 vs January 31st, 2018, Analog Devices reported revenue of $1,541.10MM vs $1,566.87MM (down 1.64%) and analysts estimated basic earnings per share $0.96 vs $0.79 (up 21.52%). For the twelve months ended October 31st, 2018 vs October 31st, 2017, Analog Devices reported revenue of $6,200.94MM vs $5,107.50MM (up 21.41%) and analysts estimated basic earnings per share $4.02 vs $2.09 (up 92.34%). Analysts expect earnings to be released on May 29th, 2019. The report will be for the fiscal period ending April 30th, 2019. The reported EPS for the same quarter last year was $1.45. The estimated EPS forecast for the next fiscal year is $5.98 and is expected to report on November 19th, 2019.

To read the full Analog Devices, Inc. (ADI) report, download it here: https://MarketSourceResearch.com/register/?so=ADI

-----------------------------------------

ATARA BIOTHERAPEUTICS, INC. (ATRA) REPORT OVERVIEW

Atara Biotherapeutics' Recent Financial Performance

Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$1.05. The estimated EPS forecast for the next fiscal year is -$5.70 and is expected to report on February 25th, 2020.

To read the full Atara Biotherapeutics, Inc. (ATRA) report, download it here: https://MarketSourceResearch.com/register/?so=ATRA

-----------------------------------------

CIGNA CORPORATION (CI) REPORT OVERVIEW

Cigna's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Cigna reported revenue of $14,336.00MM vs $10,418.00MM (up 37.61%) and analysts estimated basic earnings per share $0.41 vs $1.13 (down 63.72%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Cigna reported revenue of $48,650.00MM vs $41,806.00MM (up 16.37%) and analysts estimated basic earnings per share $10.69 vs $8.92 (up 19.84%). Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $4.11. The estimated EPS forecast for the next fiscal year is $18.51 and is expected to report on February 7th, 2020.

To read the full Cigna Corporation (CI) report, download it here: https://MarketSourceResearch.com/register/?so=CI

-----------------------------------------

SOLARIS OILFIELD INFRASTRUCTURE, INC. (SOI) REPORT OVERVIEW

Solaris Oilfield Infrastructure's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Solaris Oilfield Infrastructure reported revenue of $57.34MM vs $25.20MM (up 127.49%) and basic earnings per share $0.47 vs $0.14 (up 235.71%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Solaris Oilfield Infrastructure reported revenue of $197.20MM vs $67.40MM (up 192.60%) and analysts estimated basic earnings per share $1.60 vs $0.28 (up 471.43%). Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.31. The estimated EPS forecast for the next fiscal year is $2.31 and is expected to report on February 26th, 2020.

To read the full Solaris Oilfield Infrastructure, Inc. (SOI) report, download it here: https://MarketSourceResearch.com/register/?so=SOI

-----------------------------------------

ERIE INDEMNITY COMPANY (ERIE) REPORT OVERVIEW

Erie Indemnity's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Erie Indemnity reported revenue of $576.47MM vs $401.40MM (up 43.61%) and analysts estimated basic earnings per share $1.35 vs $0.68 (up 98.53%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Erie Indemnity reported revenue of $2,382.21MM vs $1,691.77MM (up 40.81%) and analysts estimated basic earnings per share $6.24 vs $4.26 (up 46.48%). Analysts expect earnings to be released on April 25th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $1.26. The estimated EPS forecast for the next fiscal year is $6.45 and is expected to report on February 20th, 2020.

To read the full Erie Indemnity Company (ERIE) report, download it here: https://MarketSourceResearch.com/register/?so=ERIE

-----------------------------------------

DOVA PHARMACEUTICALS, INC. (DOVA) REPORT OVERVIEW

Dova Pharmaceuticals' Recent Financial Performance

Analysts expect earnings to be released on May 8th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.52. The estimated EPS forecast for the next fiscal year is -$0.58 and is expected to report on March 3rd, 2020.

To read the full Dova Pharmaceuticals, Inc. (DOVA) report, download it here: https://MarketSourceResearch.com/register/?so=DOVA

-----------------------------------------

ABOUT MARKET SOURCE RESEARCH

Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.

REGISTERED MEMBER STATUS

Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at compliance@MarketSourceResearch.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:

Jim Patterson, Media Department

Office: +1 (704) 343-6361

E-mail: media@MarketSourceResearch.com

© 2019 Market Source Research. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@MarketSourceResearch.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Related content
13 Sep - 
Atara Biotherapeutics Reports Early Findings of Potenti..
09 Sep - 
Atara Biotherapeutics to Present Initial Efficacy and A..
28 Aug - 
Atara Biotherapeutics to Participate in Citi 14th Annua..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
UPDATE - Yoko Ono and John Lennon Educational Tour Bus “Imagine A City With No Gun Violence!”
2
Translate Bio Announces Pricing of Public Offering of Common Stock
3
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Pluralsight, Inc. - PS
4
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SAExploration Holdings, Inc. - SAEX
5
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

Related stock quotes

Analog Devices Inc 115.28 0.0% Stock price increasing
Atara Biotherapeutics In.. 15.64 4.3% Stock price increasing
Cigna Corporation 161.50 -2.4% Stock price decreasing
Erie Indemnity Company 210.23 2.0% Stock price increasing
Solaris Oilfield Infrast.. 13.65 -7.6% Stock price decreasing

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
18 September 2019 11:24:46
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190829.2 - EUROWEB6 - 2019-09-18 12:24:46 - 2019-09-18 11:24:46 - 1000 - Website: OKAY